GlassScriptPhysician profile
Donald Carl Gerhardt
NPI 1619921673
$2,952.01
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $176 · 2021: $621 · 2022: $1,090 · 2023: $679 · 2024: $20.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $995.86 | 2019-2023 | Stelara |
| Abbvie INC. | $570.74 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.04 | 2020-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.56 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $115.32 | 2021-2023 | |
| Pfizer INC. | $113.36 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $105.37 | 2019-2022 | |
| Mauna Kea Technologies, INC. | $101.49 | 2019-2024 | |
| Medtronic, INC. | $87.92 | 2021 | |
| Allergan, INC. | $82.38 | 2019-2020 | |
| Celgene Corporation | $79.43 | 2022-2023 | Zeposia |
| Amgen INC. | $69.67 | 2022-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $58.81 | 2022-2023 | Ocaliva |
| Qol Medical, LLC | $42.88 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.36 | 2022-2023 | Linzess |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $26.87 | 2023 | Linx Reflux Management System |
| Pinnacle Biologics, INC | $23.31 | 2023 | Photofrin |
| Genzyme Corporation | $22.82 | 2023 | |
| Braintree Laboratories, INC. | $19.25 | 2021 | |
| Organon LLC | $18.49 | 2022 | |
| Fresenius Kabi USA, LLC | $16.62 | 2023 | Smoflipid |
| Glaxosmithkline, LLC. | $13.43 | 2022 | |
| Alfasigma USA, INC. | $13.02 | 2022 | |
| Medtronic USA, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Gerhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.